Citation Impact
Citing Papers
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
2014 Standout
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer
2018
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
2016 Standout
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
2015
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
2011
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Regulatory T-cell directed therapies in liver diseases
2013 StandoutNobel
ENTPD1/CD39 is a promising therapeutic target in oncology
2012
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
2013
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
Elevated Pre–Antiretroviral Therapy CD39+CD8+ T Cell Frequency Is Associated With Early Mortality in Advanced Human Immunodeficiency Virus/Tuberculosis Co-infection
2017 StandoutNobel
Innate and adaptive immune cells in the tumor microenvironment
2013 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
2014
Regulatory T Cells
2010
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
The immune contexture in cancer prognosis and treatment
2017 Standout
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
2010
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Complement: a key system for immune surveillance and homeostasis
2010 Standout
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Intracellular Fragmentation of Bone Resorption Products by Reactive Oxygen Species Generated by Osteoclastic Tartrate-resistant Acid Phosphatase
1999
Mice lacking tartrate‐resistant acid phosphatase (Acp 5) have disordered macrophage inflammatory responses and reduced clearance of the pathogen, Staphylococcus aureus
2001 StandoutNobel
DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma
2009
Off to a slow start: Under-development of the complement system in term newborns is more substantial following premature birth
2011
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy
2015
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Cancer immunotherapy
2012
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
2009
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
2017 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study.
2006
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
2009 Standout
Regulatory T cells in cancer immunotherapy
2014 StandoutNobel
Neutrophils in cancer: neutral no more
2016 Standout
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
Altered Collagen in Tartrate-Resistant Acid Phosphatase (TRAP)-Deficient Mice: A Role for TRAP in Bone Collagen Metabolism
2007 StandoutNobel
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
Tartrate-resistant purple acid phosphatase is synthesized as a latent proenzyme and activated by cysteine proteinases
1999
Macrophage Polarization
2016 Standout
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
2011 Standout
The Emerging Role of Immunosurveillance in Dictating Metastatic Spread in Breast Cancer
2013
Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”
2014
Evolution of the immune system in humans from infancy to old age
2015 Standout
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Tartrate-resistant Acid Phosphatase (Acp 5): Identification in Diverse Human Tissues and Dendritic Cells
2001
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Overlapping functions of lysosomal acid phosphatase (LAP) and tartrate-resistant acid phosphatase (Acp5) revealed by doubly deficient mice
2001 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
TRACP Influences Th1 Pathways by Affecting Dendritic Cell Function
2006 StandoutNobel
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
2016
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
2014 StandoutNobel
Expression and Distribution of Tartrate-resistant Purple Acid Phosphatase in the Rat Nervous System
2001
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
2017 Standout
Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma
2012
Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
2010
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
2014 Standout
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
2013 Standout
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
In vivoInhibition of Human CD19-Targeted Effector T Cells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B Cell Malignancy
2011
Works of Sheron C. Lear being referenced
Transient T cell depletion causes regression of melanoma metastases
2008
Localization of tartrate-resistant acid phosphatase in human placenta
1996
Immunohistochemical Detection of Tartrate-Resistant Acid Phosphatase in Non-Hematopoietic Human Tissues
1995
Complement component 9 activation, consumption, and neuronal deposition in the post-hypoxic–ischemic central nervous system of human newborn infants
2005